Q1 2024 · 13F-HR
MPM BioImpact LLCholdings as filed
Filed 2024-05-15 · accession 0000950123-24-005704
$622.0M
Reported value
38
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 230031106 | CGEM | Cullinan Oncology, Inc. | $130.3M | 21.0% | 7,648,268 | Common | SOLE |
| 374163103 | GERN | Geron Corporation | $34.6M | 5.56% | 10,475,675 | Common | SOLE |
| 462260100 | IOVA | Iovance Biotherapeutics Inc | $32.6M | 5.24% | 2,200,000 | Common | SOLE |
| 98943L107 | ZNTL | Zentalis Pharmaceuticals, Inc. | $23.9M | 3.84% | 1,516,183 | Common | SOLE |
| 46565G104 | 5E7 | iTeos Therapeutics, Inc. | $23.8M | 3.83% | 1,745,943 | Common | SOLE |
| 869367102 | — | Sutro Biopharma, Inc. | $23.1M | 3.72% | 4,096,619 | Common | SOLE |
| 22663K107 | CRNX | Crinetics Pharmaceuticals Inc. | $22.5M | 3.62% | 480,588 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals, Inc. | $22.1M | 3.56% | 1,953,690 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals inc | $16.4M | 2.64% | 61,399 | Common | SOLE |
| 632307104 | NTRA | Natera Inc | $15.8M | 2.54% | 172,413 | Common | SOLE |
| 95075A107 | HOWL | Werewolf Therapeutics, Inc. | $15.5M | 2.49% | 2,388,011 | Common | SOLE |
| 61559X104 | MLTX | Moonlake Immunotherapeutics | $14.9M | 2.39% | 296,050 | Common | SOLE |
| 05337M104 | — | Avadel Pharmaceuticals PLC | $14.7M | 2.37% | 871,149 | Common | SOLE |
| 457669307 | INSM | Insmed Incorporated | $14.4M | 2.32% | 530,794 | Common | SOLE |
| 00166B105 | ALXO | ALX Oncology Holdings Inc. | $14.1M | 2.27% | 1,268,471 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $12.3M | 1.98% | 150,000 | Common | SOLE |
| 45826J105 | NTLA | Intellia Therapeutics, Inc. | $11.9M | 1.91% | 432,598 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO Inc. | $11.6M | 1.86% | 549,078 | Common | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc | $11.5M | 1.84% | 245,590 | Common | SOLE |
| 61775R105 | MORFUSD | MORPHIC HOLDING INC | $11.5M | 1.84% | 325,333 | Common | SOLE |
| 282559103 | ETNBGBP | 89Bio Inc | $11.3M | 1.81% | 967,742 | Common | SOLE |
| 92790C104 | VRDN | Viridian Therapeutics Inc | $10.8M | 1.73% | 614,010 | Common | SOLE |
| 359616109 | FULC | Fulcrum Therapeutics Inc | $10.7M | 1.73% | 1,137,108 | Common | SOLE |
| 98422E103 | XERS | Xeris Biopharma Holdings Inc | $9.2M | 1.48% | 4,166,496 | Common | SOLE |
| 05464T104 | AXSM | Axsome Therapeutics, Inc. | $9.1M | 1.46% | 114,127 | Common | SOLE |
| 483497103 | KALV | Kalvista Pharmaceuticals Inc | $9.0M | 1.45% | 760,722 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $8.8M | 1.42% | 273,217 | Common | SOLE |
| 92539P101 | — | Verve Therapeutics, Inc | $8.5M | 1.36% | 638,163 | Common | SOLE |
| 03152W109 | AM6 | Amicus Therapeutics Inc. | $8.5M | 1.36% | 718,970 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics Inc | $8.4M | 1.35% | 332,924 | Common | SOLE |
| 00653A107 | ADAPY | Adaptimmune Therapeutics plc | $8.1M | 1.29% | 5,095,912 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics Inc | $8.0M | 1.29% | 441,259 | Common | SOLE |
| 760273102 | RPTX | Repare Therapeutics, Inc. | $7.7M | 1.24% | 1,639,849 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics Inc. | $6.9M | 1.11% | 832,017 | Common | SOLE |
| 254604101 | IRON | Disc Medicine Inc | $6.9M | 1.11% | 110,779 | Common | SOLE |
| 89532M101 | TRVI | Trevi Therapeutics Inc | $4.6M | 0.74% | 1,340,960 | Common | SOLE |
| N44445909 | — | Immatics NV | $4.2M | 0.67% | 395,237 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics, Inc. | $3.9M | 0.63% | 1,971,402 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.